IHC intensity | Follow-up (Month) | Number of Recurrence | Rate, n/1000 person-month | Crude HR (95% CI) |
---|---|---|---|---|
Beclin-1 | ||||
 0 | 581.14 | 8 | 13.77 | 1.0 |
 1 | 812.20 | 22 | 27.09 | 1.55 (0.69–3.50) |
 2 | 496.95 | 35 | 70.43 | 2.75 (1.26–6.00) |
 3 | 310.27 | 20 | 64.46 | 3.19 (1.38–7.37) |
 Negative | 581.14 | 8 | 13.77 | 1.0 |
 Positive | 1619.42 | 77 | 47.55 | 2.27 (1.09–4.75) |
ARID1A | ||||
 0 | 994.59 | 23 | 23.13 | 1.0 |
 1 | 641.70 | 34 | 52.98 | 1.73 (1.01–2.94) |
 2 | 480.94 | 23 | 47.82 | 1.76 (0.98–3.14) |
 3 | 83.33 | 5 | 60.00 | 1.47 (0.56–3.89) |
 Negative | 994.59 | 23 | 23.13 | 1.0 |
 Positive | 1205.97 | 62 | 51.41 | 1.71 (1.06–2.78) |
IDH1 | ||||
 0 | 258.99 | 5 | 19.31 | 1.0 |
 1 | 418.98 | 20 | 47.74 | 1.56 (0.58–4.16) |
 2 | 1071.72 | 35 | 32.66 | 1.14 (0.44–2.90) |
 3 | 450.87 | 25 | 55.45 | 1.38 (0.53–3.63) |
 Negative | 258.99 | 5 | 19.31 | 1.0 |
 Positive | 1941.57 | 80 | 41.20 | 1.29 (0.52–3.20) |
CA9 | ||||
 0 | 541.80 | 12 | 22.15 | 1.0 |
 1 | 420.68 | 26 | 61.80 | 1.12 (0.56–2.23) |
 2 | 695.73 | 27 | 38.81 | 0.88 (0.44–1.75) |
 3 | 542.35 | 20 | 36.88 | 0.91 (0.44–1.86) |
 Negative | 541.80 | 12 | 22.15 | 1.0 |
 Positive | 1658.76 | 73 | 44.01 | 0.96 (0.52–1.77) |